BML-278

• UNSPSC Description:

  BML-278 is a SIRT1 activator (EC150: 1 μM). BML-278 increases H3K9 methylation and inhibits H3K9 acetylation in both the paternal and maternal pronucleus. BML-278 improves early embryonic development. BML-278 arrests the cell cycle at the G1/S phase, and reduces senescence in primary human mesenchymal cells. BML-278 reduces tubulin acetylation in U937 cells. BML-278 also increases mitochondrial density in murine C2C12 myoblasts[1][2].

• Target Antigen:

  Histone Methyltransferase; Sirtuin

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage;Epigenetics

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/bml-278.html

• Purity:

  98.49

• Solubility:

  DMSO : 10 mg/mL (ultrasonic;warming;heat to 60°C)

• Smiles:

  CCOC(C1=CN(C=C(C(OCC)=O)C1C2=CC=CC=C2)CC3=CC=CC=C3)=O

• Molecular Weight:

  391.46

• References & Citations:

  [1]Adamkova K, et al. SIRT1-dependent modulation of methylation and acetylation of histone H3 on lysine 9 (H3K9) in the zygotic pronuclei improves porcine embryo development. J Anim Sci Biotechnol. 2017 Nov 1;8:83.|[2]Mai A, et al. Study of 1,4-dihydropyridine structural scaffold: discovery of novel sirtuin activators and inhibitors. J Med Chem. 2009 Sep 10;52(17):5496-504.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  120533-76-8